RE:RE:PartnershipsOne thing's for sure, is that SZLS has been fully aware of GRAIL and other competitors. So there will be no surprize.
SZLS even posted a GRAIL paper recenlty. Like if they were sending a message that they're not afraid of competition.
No matter what, SZLS knows all these recent news about GRAIL, so one would be advised to adjust accordingly.
Liquid biopsy is the future. There's not a single big pharma player that is not already looking, shopping, making plans, teaming up with players in order to enter this market. It's a positioning game. Big healthcare networks (network of hospitals), insurance companies, etc ... will all benefit of this new era.
GRAIL has been able lately to attract big names. We own a technology, so it's fair to assume that we've forged relationships with complementary partners. The SZLS CEO hinted us on this over the recent months, without disclosing names. It is impossible that SZLS goes all along in this market. It needs partners. Just like GRAIL needed partners. So partner-day is approaching. There are still big names not having announced their dancing partners.
SZLS has no more room to delay the launch of Aristotle, when you see that GRAIL has announced on January 11 that it will launch its Galleri test in Q2
(Q2 2021 Introduction of Galleri). But to me, it's the Grail March 2nd and March 16 news releases that are more telling as they give us numbers. But GRAIL has been able to sign with big pharmas too. They went full circle so far.
Competition is always a good thing as it forces you to focus on the real things, to set your priorities at the right place, to accelerate networking, etc ... It's a race. And what's at stake it the first mover advantage.
First movers in an industry are almost always followed by competitors that attempt to capitalize on the first mover's success and gain market share. Most often, the first mover has established sufficient market share and a solid enough customer base that it maintains the majority of the market. News | Press and Media | Media Kits | GRAIL Life Sciences GRAIL,
AccessHope Collaborate to Optimize Patient and Healthcare Provider Experience for Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test
March 16, 2021
AccessHope serves more than 2 million members who have cancer support benefits through 42 employers, including 18 Fortune 500 companies. GRAIL
Announces First Health System to Offer Galleri, Novel Multi-Cancer Early Detection Blood Test
March 2, 2021
Leading Health System Providence is First to Bring the Innovation to Patients and Communities The Galleri test initially will be used by Providence at its California, Washington, and Oregon points of care, and could eventually be available across Providence’s entire seven-state footprint that includes more than 50 hospitals and nearly 1,100 health clinics serving 5 million patients. Providence aims to pursue effective ways to identify cancer earlier in patient lives, and will integrate the Galleri test into clinical care to help drive earlier detection of multiple cancers Multi-Cancer Early Detection Company GRAIL Now Hiring For
State-Of-The-Art Laboratory Facility in Research Triangle Park
February 25, 2021
GRAIL and
Quest Diagnostics Announce Collaboration to Support Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test
February 23, 2021
GRAIL Announces
Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease
January 11, 2021
GRAIL Confirms
Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test
January 11, 2021
New Research Suggests Multi-Cancer Early Detection Blood Test Could Reduce Late-Stage Cancer Diagnoses by More Than Half
December 16, 2020
GRAIL and
UK Government to Make Galleri Multi-Cancer Early Detection Blood Test Available to Patients
November 26, 2020
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
September 21, 2020
GRAIL Announces Filing of Registration Statement for Proposed Initial Public Offering
September 9, 2020
Cleveland Clinic Joins Interventional Study Using GRAIL’s Multi-Cancer Early Detection Test to Help Guide Clinical Care
August 6, 2020